ADMA Biologics ADMA faced a sharp pullback in late March after Culper Research released a critical report on March 24, 2026. The firm disclosed a short position in ADMA shares, amplifying market reaction and triggering near-term volatility.
Management responded swiftly, reaffirming its commitment to transparent financial reporting and strict compliance with U.S. SEC regulations and GAAP standards. The company strongly refuted the report, describing it as speculative and based on unidentified sources, while also highlighting multiple inaccuracies. At the same time, ADMA indicated that it is reviewing the claims—an approach that may help reassure investors and mitigate reputational risk.
ADMA’s rebuttal appears to be gaining traction. The company highlighted continued strength in its core immunoglobulin franchise, particularly Asceniv, with both distributor and end-market demand remaining robust. Management also addressed concerns around alleged “channel stuffing,” noting that inventory levels are consistent with industry norms and have actually declined in recent months.
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. It is indicated for the treatment of primary immunodeficiency disease (PIDD) or inborn errors of immunity in adults and adolescents.
ADMA operates in a structurally expanding IVIG market, benefiting from rising demand for immune therapies. The company is also driving margin expansion through yield-enhanced production processes, while improving capital efficiency across operations.
Looking ahead, management’s long-term roadmap, targeting annual revenues exceeding $1 billion, appears achievable if current demand trends persist.
Competition in the Plasma Therapy Market
ADMA Biologics competes with Grifols GRFS and Takeda TAK for plasma-derived products.
GRFS is a leading producer of plasma derivatives globally, ranking among the three largest producers in the industry in terms of total sales, alongside Takeda and CSL Group. The main plasma products that Grifols manufactures are IG, Factor VIII, Alpha 1 (A1PI) and albumin. Grifols also manufactures intramuscular (hyperimmune) immunoglobulins (IGs), ATIII, Factor IX and plasma thromboplastin component.
Grifols has a strong presence in various segments of the plasma derivatives industry, including A1PI, IG and albumin, aided by its dominant position in plasma collection centers and fractionation capacity.
Takeda’s broad immunoglobulin portfolio includes Hyqvia, Cuvitru, Gammagard Liquid and Gammagard Liquid ECR. The company is developing next-generation IG products with 20% facilitated SCIG (TAK-881). It is also pursuing other early-stage opportunities (e.g., hypersialylated Immunoglobulin [hsIgG]) that would diversify its portfolio further.
ADMA’s Price Performance, Valuation & Estimates
Shares of ADMA have lost 34.1% in the past month compared with the industry’s loss of 0.5%.
Image Source: Zacks Investment Research
From a valuation perspective, ADMA is expensive at this moment. Going by the price/sales ratio, ADMA’s shares currently trade at 3.73x forward sales, higher than its mean of 3.69x and the industry’s 2.08x.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for ADMA’s 2026 earnings per share has moved north to 96 cents in the past 60 days while that for 2027 has remained stable at $1.38.
Image Source: Zacks Investment Research
ADMA currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Grifols, S.A. (GRFS): Free Stock Analysis Report
ADMA Biologics Inc (ADMA): Free Stock Analysis Report
Takeda Pharmaceutical Co. (TAK): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).